MARGINAL ZONE LYMPHOMA

This study compares a very low dose of radiation (4 Gy) to the standard dose (24 Gy) for people with follicular or marginal zone lymphoma. The goal is to see if the low dose works just as well to control the cancer and prevent new spots from forming, while causing fewer side effe…

This study tests an experimental oral drug, AS-1763, in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see how well the drug controls the cancer. About 120 participa…

This study tests an investigational drug called epcoritamab in 25 adults with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. The drug is given as an injection under the skin to help the immune system attack cancer cells. The main goal is to see how many pati…

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This study tests a drug called pemigatinib in 27 adults with certain types of B-cell non-Hodgkin lymphoma that have returned or not responded to at least two prior treatments. The main goal is to see how many patients have their tumors shrink or disappear after seven cycles of tr…

This study looks at whether carefully managing high blood pressure can reduce the risk of serious heart events in people with B-cell cancers (like CLL or lymphoma) who are taking BTKi drugs. About 100 participants will have their blood pressure closely monitored and treated if it…

This early-phase study tests a new treatment for adults with B-cell lymphomas (like certain types of non-Hodgkin lymphoma) that have come back or not responded to prior therapies. The treatment combines a targeted drug called pirtobrutinib with specially engineered immune cells (…

This study tests whether two drugs, rituximab and venetoclax, work well together for people with untreated marginal zone lymphoma, a slow-growing blood cancer. About 33 participants will receive the combination to see how many achieve complete remission. The goal is to find a mor…

This study tests whether a combination of two drugs, mosunetuzumab and lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has returned or not responded to prior therapy. About 260 adults who have had 1 to 3 prior treatments will be ran…

This study tests a drug called orelabrutinib in people with marginal zone lymphoma who have not had any prior treatment. The goal is to see if the drug can shrink or control the cancer. About 30 adults will take the pill and be monitored for side effects and how well the cancer r…

This study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not responded to standard treatments. The therapy aims to help the body fight cancer cells by targeting a protein called CD19 found on these…

This study tests the safety and effectiveness of combining two drugs, rituximab and zanubrutinib, for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 participants will receive the drug combination, and researchers will measure how well the tumors shr…

This study tests a new drug, orelabrutinib, combined with chemotherapy for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. About 69 participants will receive the combo, followed by long-term orelabrutinib maintenance. The goal is to see if this ap…

This study tests two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing lymphomas. The goal is to see if the combination can shrink tumors and keep the cancer under control. About 49 adults will take part. The treatment is no…

This early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…

This study tests a new drug called BGB-16673 for people with certain B-cell blood cancers that have come back or not responded to other treatments. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first finding the best dose, then t…

This early-phase study tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with Non-Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check safety and find the right do…

This study is observing adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking the drug zanubrutinib as part of their normal care. Researchers will track hospital visits and quality of life over tim…